Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVX NASDAQ:AVDL NYSE:QGEN NASDAQ:TGTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$101.18+2.0%$114.06$5.69▼$148.83$8.08B0.691.43 million shs1.34 million shsAVDLAvadel Pharmaceuticals$21.39-1.1%$21.48$8.19▼$23.57$2.09B1.312.03 million shs35.02 million shsQGENQiagen$36.68-0.7%$36.68$32.53▼$57.81$7.56B0.662.30 million shs869,436 shsTGTXTG Therapeutics$54.77+2.9%$40.19$25.28▼$57.38$8.38B1.682.15 million shs1.43 million shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax0.00%+2.69%-18.72%-14.10%+1,560.80%AVDLAvadel Pharmaceuticals0.00%0.00%0.00%0.00%+133.01%QGENQiagen0.00%-0.19%+5.02%-6.41%-24.76%TGTXTG Therapeutics0.00%+7.47%+36.92%+74.78%+47.75%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$101.18+2.0%$114.06$5.69▼$148.83$8.08B0.691.43 million shs1.34 million shsAVDLAvadel Pharmaceuticals$21.39-1.1%$21.48$8.19▼$23.57$2.09B1.312.03 million shs35.02 million shsQGENQiagen$36.68-0.7%$36.68$32.53▼$57.81$7.56B0.662.30 million shs869,436 shsTGTXTG Therapeutics$54.77+2.9%$40.19$25.28▼$57.38$8.38B1.682.15 million shs1.43 million shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax0.00%+2.69%-18.72%-14.10%+1,560.80%AVDLAvadel Pharmaceuticals0.00%0.00%0.00%0.00%+133.01%QGENQiagen0.00%-0.19%+5.02%-6.41%-24.76%TGTXTG Therapeutics0.00%+7.47%+36.92%+74.78%+47.75%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVXAbivax 2.73Moderate Buy$130.0828.56% UpsideAVDLAvadel Pharmaceuticals 2.00Hold$20.20-5.56% DownsideQGENQiagen 2.42Hold$44.9822.63% UpsideTGTXTG Therapeutics 2.71Moderate Buy$52.50-4.15% DownsideCurrent Analyst Ratings BreakdownLatest AVDL, ABVX, QGEN, and TGTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2026ABVXAbivax BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$150.006/3/2026ABVXAbivax Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$136.006/3/2026ABVXAbivax Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/2/2026ABVXAbivax Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$140.00 ➝ $135.006/2/2026ABVXAbivax Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$145.00 ➝ $132.006/2/2026ABVXAbivax CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/2/2026ABVXAbivax Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$160.00 ➝ $90.006/2/2026ABVXAbivax Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$131.00 ➝ $187.006/2/2026ABVXAbivax WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderperform ➝ Neutral$110.00 ➝ $90.006/2/2026ABVXAbivax BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$150.006/1/2026TGTXTG Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold(Data available from 6/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVXAbivaxN/AN/AN/AN/A$6.57 per shareN/AAVDLAvadel Pharmaceuticals$248.52M8.41N/AN/A$0.77 per share27.78QGENQiagen$2.09B3.62$3.38 per share10.85$17.89 per share2.05TGTXTG Therapeutics$616.29M13.60$2.88 per share18.99$4.08 per share13.42Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVXAbivax-$380.27M-$5.21N/AN/AN/AN/A-99.02%-70.26%N/AAVDLAvadel Pharmaceuticals-$48.83MN/AN/A356.50N/A-0.11%-0.33%-0.15%N/AQGENQiagen$424.88M$1.9119.1613.893.6819.16%14.40%8.40%8/4/2026 (Estimated)TGTXTG Therapeutics$447.18M$2.8619.1519.92N/A65.95%88.73%43.44%8/3/2026 (Estimated)Latest AVDL, ABVX, QGEN, and TGTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/22/2026Q1 2026ABVXAbivax-$0.9359-$0.71+$0.2259-$0.71$0.40 million$1.56 million5/7/2026Q1 2026QGENQiagen$0.54$0.54N/A$0.33$496.15 million$492.32 million5/6/2026Q1 2026TGTXTG Therapeutics$0.23$0.12-$0.11$0.12$200.33 million$204.92 million3/23/2026Q4 2025ABVXAbivax-$2.24-$1.20+$1.04-$1.20$1.80 million$0.52 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABVXAbivaxN/AN/AN/AN/AN/AAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/AQGENQiagen$0.260.71%N/A13.61%N/ATGTXTG TherapeuticsN/AN/AN/AN/AN/ALatest AVDL, ABVX, QGEN, and TGTX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/11/2026QGENQiagenannual$0.351.04%7/7/20267/7/20267/14/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVXAbivaxN/A8.258.25AVDLAvadel PharmaceuticalsN/A2.762.37QGENQiagen0.493.212.57TGTXTG Therapeutics1.285.815.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVXAbivax47.91%AVDLAvadel Pharmaceuticals69.19%QGENQiagen70.00%TGTXTG Therapeutics58.58%Insider OwnershipCompanyInsider OwnershipABVXAbivaxN/AAVDLAvadel Pharmaceuticals5.20%QGENQiagen9.00%TGTXTG Therapeutics8.87%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVXAbivax6179.77 millionN/ANot OptionableAVDLAvadel Pharmaceuticals7097.66 million92.58 millionOptionableQGENQiagen5,654206.07 million187.53 millionOptionableTGTXTG Therapeutics290153.08 million139.51 millionOptionableAVDL, ABVX, QGEN, and TGTX HeadlinesRecent News About These CompaniesIs TG Therapeutics, Inc. (TGTX) A Good Stock To Buy Now?June 19 at 1:30 PM | insidermonkey.comIs TG Therapeutics, Inc. (TGTX) A Good Stock To Buy Now?June 19 at 12:30 PM | finance.yahoo.comTG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Rating of "Moderate Buy" from BrokeragesJune 19 at 4:05 AM | americanbankingnews.comTG Therapeutics Stock Rises Thursday: What's Driving The Gains?June 18, 2026 | benzinga.comTGTX Stock Continues Rally For 8 Straight Sessions On New BRIUMVI Clinical DataJune 17, 2026 | msn.comTG Therapeutics stock is on a hot streak: Why it's up 70% and climbingJune 17, 2026 | msn.comTG Therapeutics (NASDAQ:TGTX) Hits New 52-Week High - Still a Buy?June 16, 2026 | americanbankingnews.comTG Therapeutics (NASDAQ:TGTX) Reaches New 12-Month High - Should You Buy?June 12, 2026 | americanbankingnews.comTG Therapeutics, Inc. $TGTX Shares Sold by WINTON GROUP LtdJune 11, 2026 | marketbeat.comTG Therapeutics (TGTX) Soars 7.5%: Is Further Upside Left in the Stock?June 11, 2026 | zacks.comWhy TG Therapeutics (TGTX) Is Up 18.4% After Advancing At‑Home Subcutaneous BRIUMVI In MS TreatmentJune 10, 2026 | finance.yahoo.comTGTX Rises on Positive Phase I Data for Subcutaneous Briumvi in MGJune 10, 2026 | zacks.comTGTX Stock Jumps 5% On Positive Early Data For At-Home BRIUMVI In Muscle DiseaseJune 10, 2026 | finance.yahoo.comTG Therapeutics, Inc. (TGTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 9, 2026 | seekingalpha.comTG Thera posts early-stage data for Briumvi in myasthenia gravis; launches mid-stage trialJune 9, 2026 | seekingalpha.comTG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized ...June 9, 2026 | finance.yahoo.comA Look At TG Therapeutics (TGTX) Valuation After Recent Positive BRIUMVI Trial UpdatesJune 9, 2026 | finance.yahoo.comTG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 TrialJune 9, 2026 | globenewswire.comB. Riley Securities Remains a Buy on TG Therapeutics (TGTX)June 8, 2026 | theglobeandmail.comWhy Is TG Therapeutics (TGTX) Down 5.7% Since Last Earnings Report?June 5, 2026 | zacks.comTG Therapeutics rises on early-stage trial data for Briumvi injectableJune 4, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAVDL, ABVX, QGEN, and TGTX Company DescriptionsAbivax NASDAQ:ABVX$101.18 +2.03 (+2.05%) As of 01:57 PM Eastern This is a fair market value price provided by Massive. Learn more.ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.Avadel Pharmaceuticals NASDAQ:AVDLAvadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.Qiagen NYSE:QGEN$36.68 -0.27 (-0.74%) As of 01:57 PM Eastern This is a fair market value price provided by Massive. Learn more.QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.TG Therapeutics NASDAQ:TGTX$54.77 +1.55 (+2.91%) As of 01:57 PM Eastern This is a fair market value price provided by Massive. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas USA Today's Digital Revival Is Gaining Steam, But With Plenty of Risk Burlington Is Winning Over Shoppers But Investors Need Patience Investors Are Buying Into Sweetgreen Again—Should They? MarketBeat Week in Review – 06/15 - 06/19 Cheesecake Factory Stock Is Up Over 50%—Is There Room for More CAKE? Applied Materials Stock Looks Pricey—Can AI Demand Justify the Rally? Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
